Sunshine Guojian (688336.SH) Issues Positive Profit Alert, Forecasts 2025 Net Profit Attributable to Shareholders of Approx. 2.9 Billion Yuan, Up 311.35%

Stock News01-26

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has released its annual performance forecast for 2025. The company anticipates achieving a net profit attributable to the owners of the parent company of approximately 2.9 billion yuan for the full year 2025. This represents an increase of about 2.195 billion yuan compared to the same period last year, marking a significant year-on-year surge of approximately 311.35%. Furthermore, the company expects a net profit attributable to the owners of the parent company after deducting non-recurring gains and losses to be around 2.8 billion yuan. This figure indicates an increase of roughly 2.554 billion yuan from the prior year, equating to a staggering year-on-year growth of about 1,038.21%. During the reporting period, the company entered into a significant collaboration with Pfizer Inc. As a result of this partnership, Sunshine Guojian received an upfront payment for the licensing of its 707 project from Pfizer, recognizing corresponding revenue of approximately 2.89 billion Chinese yuan. This transaction was the primary driver behind the substantial growth in the company's operating revenue, net profit attributable to shareholders, and core net profit for the 2025 fiscal year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164647335?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164647335","market":"sh","top_or_hot":-1,"title":"Sunshine Guojian (688336.SH) Issues Positive Profit Alert, Forecasts 2025 Net Profit Attributable to Shareholders of Approx. 2.9 Billion Yuan, Up 311.35%","media":"Stock News","content":"<p>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has released its annual performance forecast for 2025. The company anticipates achieving a net profit attributable to the owners of the parent company of approximately 2.9 billion yuan for the full year 2025. This represents an increase of about 2.195 billion yuan compared to the same period last year, marking a significant year-on-year surge of approximately 311.35%. Furthermore, the company expects a net profit attributable to the owners of the parent company after deducting non-recurring gains and losses to be around 2.8 billion yuan. This figure indicates an increase of roughly 2.554 billion yuan from the prior year, equating to a staggering year-on-year growth of about 1,038.21%. During the reporting period, the company entered into a significant collaboration with Pfizer Inc. As a result of this partnership, Sunshine Guojian received an upfront payment for the licensing of its 707 project from Pfizer, recognizing corresponding revenue of approximately 2.89 billion Chinese yuan. This transaction was the primary driver behind the substantial growth in the company's operating revenue, net profit attributable to shareholders, and core net profit for the 2025 fiscal year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunshine Guojian (688336.SH) Issues Positive Profit Alert, Forecasts 2025 Net Profit Attributable to Shareholders of Approx. 2.9 Billion Yuan, Up 311.35%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunshine Guojian (688336.SH) Issues Positive Profit Alert, Forecasts 2025 Net Profit Attributable to Shareholders of Approx. 2.9 Billion Yuan, Up 311.35%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-26 19:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has released its annual performance forecast for 2025. The company anticipates achieving a net profit attributable to the owners of the parent company of approximately 2.9 billion yuan for the full year 2025. This represents an increase of about 2.195 billion yuan compared to the same period last year, marking a significant year-on-year surge of approximately 311.35%. Furthermore, the company expects a net profit attributable to the owners of the parent company after deducting non-recurring gains and losses to be around 2.8 billion yuan. This figure indicates an increase of roughly 2.554 billion yuan from the prior year, equating to a staggering year-on-year growth of about 1,038.21%. During the reporting period, the company entered into a significant collaboration with Pfizer Inc. As a result of this partnership, Sunshine Guojian received an upfront payment for the licensing of its 707 project from Pfizer, recognizing corresponding revenue of approximately 2.89 billion Chinese yuan. This transaction was the primary driver behind the substantial growth in the company's operating revenue, net profit attributable to shareholders, and core net profit for the 2025 fiscal year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1164647335","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164647335","pubTimestamp":1769428470,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has released its annual performance forecast for 2025. The company anticipates achieving a net profit attributable to the owners of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688336":"三生国健","BK0239":"医药制造"},"translate_title":"三生国健（688336.SH）发布正面盈利预警，预计2025年归属于股东的净利润约为。29亿元，增长311.35%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688336":1},"content_text":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has released its annual performance forecast for 2025. The company anticipates achieving a net profit attributable to the owners of the parent company of approximately 2.9 billion yuan for the full year 2025. This represents an increase of about 2.195 billion yuan compared to the same period last year, marking a significant year-on-year surge of approximately 311.35%. Furthermore, the company expects a net profit attributable to the owners of the parent company after deducting non-recurring gains and losses to be around 2.8 billion yuan. This figure indicates an increase of roughly 2.554 billion yuan from the prior year, equating to a staggering year-on-year growth of about 1,038.21%. During the reporting period, the company entered into a significant collaboration with Pfizer Inc. As a result of this partnership, Sunshine Guojian received an upfront payment for the licensing of its 707 project from Pfizer, recognizing corresponding revenue of approximately 2.89 billion Chinese yuan. This transaction was the primary driver behind the substantial growth in the company's operating revenue, net profit attributable to shareholders, and core net profit for the 2025 fiscal year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164647335","isCrawlerRequest":true}